Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Masayuki Ohkura"'
Autor:
Naoto Takahashi, Jorge E. Cortes, Emiko Sakaida, Kenichi Ishizawa, Takaaki Ono, Noriko Doki, Itaru Matsumura, Valentín García-Gutiérrez, Gianantonio Rosti, Chiho Ono, Masayuki Ohkura, Yusuke Tanetsugu, Andrea Viqueira, Tim H. Brümmendorf
Publikováno v:
International Journal of Hematology. 115:838-851
Bosutinib has been investigated in multiple clinical trials globally, including Japan, for treatment of chronic myeloid leukemia (CML). A pooled analysis of seven Pfizer-sponsored clinical trials evaluated the safety of bosutinib in Japanese (n = 138
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03ba140070da2f204e96c7392d581888
https://doi.org/10.1007/s12185-022-03314-y
https://doi.org/10.1007/s12185-022-03314-y
Publikováno v:
Kansenshogaku Zasshi. 96:15-24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d8d021583c982125b3b6ccb1cc8b73a
https://doi.org/10.11150/kansenshogakuzasshi.96.15
https://doi.org/10.11150/kansenshogakuzasshi.96.15
Autor:
Mie Suzuki, Hidetoshi Hayashi, Makoto Nishio, Gerson Peltz, Takashi Nagasawa, Toyoaki Hida, Takashi Seto, Kei Fukuhara, Masayuki Ohkura, Miyako Satouchi, Yasushi Goto, Holger Thurm, Masahiro Morise, Naoyuki Nogami, Toshiaki Takahashi, Seiji Niho, Jun Sakakibara-Konishi
Publikováno v:
Cancer Science
Lorlatinib is a potent, brain‐penetrant, third‐generation anaplastic lymphoma kinase (ALK)/ROS proto‐oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) that is active against most known resistance mutations. This is an ongoing phase 1/2, multina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cafd98324b778f3492d5868e94a8541
https://doi.org/10.1111/cas.14576
https://doi.org/10.1111/cas.14576
Autor:
Tontanai Numbenjapon, Young Rok Do, Jorge E. Cortes, Liang Piu Koh, Dae Young Zang, Charles Chuah, Tim H. Brümmendorf, Kiat Hoe Ong, Masayuki Ohkura, Andrea Viqueira, Chiho Ono
Publikováno v:
International journal of hematology. 114(1)
Bosutinib is approved in the United States, Europe, Japan, and other countries for treatment of newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML), and CML resistant/intolerant to prior therapy. In the phase 3 BFORE trial (Clinicaltria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70264ffc0ec2eb03ad3961a2c6253bdc
https://pubmed.ncbi.nlm.nih.gov/33851349
https://pubmed.ncbi.nlm.nih.gov/33851349
Publikováno v:
Clinical Therapeutics.
Purpose This prospective analysis of the Japanese subpopulation of the varenicline reduce to quit study was conducted to evaluate whether results for Japanese participants were consistent with the full study population. Methods Patients received vare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea4e8fa493804b70ba451a9928719513
Publikováno v:
Clinical Therapeutics. 36:918-927
BackgroundThe efficacy of the smoking-cessation agent varenicline has been reported in Asian smokers; however, few studies have investigated factors that contribute to lapse and relapse.ObjectiveThis post hoc analysis aimed to identify predictors of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce5aa2966aeef82745a19e4f316b48a9
https://doi.org/10.1016/j.clinthera.2014.03.013
https://doi.org/10.1016/j.clinthera.2014.03.013
Autor:
Masayuki Ohkura, Masayuki Hino, Naohiro Sekiguchi, Naoto Takahashi, Itaru Matsumura, Emiko Sakaida, Kenichi Ishizawa, Yuichiro Koide, Shin Fujisawa, Yusuke Tanetsugu, Takaaki Ono, Kei Fukuhara
Publikováno v:
Blood. 134:4159-4159
Background: Bosutinib, a Src/Abl tyrosine kinase inhibitor, is approved at a starting dose of 500 mg once daily (QD) in many countries, including Japan, for patients with Philadelphia chromosome-positive (Ph+) chronic phase (CP), accelerated phase (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5d195945786560d497ef8bf5afd35cb
https://doi.org/10.1182/blood-2019-121809
https://doi.org/10.1182/blood-2019-121809
Publikováno v:
Modern Rheumatology. 23:1108-1115
To assess the long-term safety and efficacy of pregabalin for the treatment of Japanese patients with fibromyalgia (FM). This 53-week, open-label extension study was conducted at 20 study sites in Japan in patients with FM who had completed a precedi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8379e37df8897b01f29cbe9438b40361
https://doi.org/10.3109/s10165-012-0803-x
https://doi.org/10.3109/s10165-012-0803-x
Autor:
Masayuki Ohkura, Makoto Suzuki, Hiroyoshi Ohta, Akihiro Kaneko, Katsuyuki Machii, Ken‘ichi Saito
Publikováno v:
Clinical Therapeutics. 34:314-328
Although third mandibular molar extraction is a widely used and validated model of acute pain for evaluating analgesic efficacy, a large proportion of patients experience moderate or severe pain following this procedure and require analgesia. Current
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::072bdd11dbcdec0088420d4d2f60d20f
https://doi.org/10.1016/j.clinthera.2012.01.004
https://doi.org/10.1016/j.clinthera.2012.01.004
Autor:
Masayuki Ohkura, Toshinari Kamakura
Publikováno v:
Japanese Journal of Applied Statistics. 40:41-51
ロジスティック回帰モデルを小標本かつ応答変数発現確率が高い条件下または低い条件下で用いる場合，完全分離または準完全分離が生じていないかを確認することが重要である．完全
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff99eeae6bb1b91fd0de4c808c7e18ca
https://doi.org/10.5023/jappstat.40.41
https://doi.org/10.5023/jappstat.40.41